CN1048015C - 双环四氢吡唑并吡啶类化合物 - Google Patents

双环四氢吡唑并吡啶类化合物 Download PDF

Info

Publication number
CN1048015C
CN1048015C CN94193233A CN94193233A CN1048015C CN 1048015 C CN1048015 C CN 1048015C CN 94193233 A CN94193233 A CN 94193233A CN 94193233 A CN94193233 A CN 94193233A CN 1048015 C CN1048015 C CN 1048015C
Authority
CN
China
Prior art keywords
ethyl
oxo
tetrahydro
pyridine
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN94193233A
Other languages
English (en)
Chinese (zh)
Other versions
CN1129940A (zh
Inventor
艾伦·J·杜普兰蒂尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN1129940A publication Critical patent/CN1129940A/zh
Application granted granted Critical
Publication of CN1048015C publication Critical patent/CN1048015C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN94193233A 1993-07-06 1994-06-16 双环四氢吡唑并吡啶类化合物 Expired - Fee Related CN1048015C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8829293A 1993-07-06 1993-07-06
US08/088,292 1993-07-06

Publications (2)

Publication Number Publication Date
CN1129940A CN1129940A (zh) 1996-08-28
CN1048015C true CN1048015C (zh) 2000-01-05

Family

ID=22210524

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94193233A Expired - Fee Related CN1048015C (zh) 1993-07-06 1994-06-16 双环四氢吡唑并吡啶类化合物

Country Status (20)

Country Link
EP (1) EP0707585A1 (https=)
JP (1) JP2944048B2 (https=)
KR (1) KR100228949B1 (https=)
CN (1) CN1048015C (https=)
AU (1) AU695301B2 (https=)
BR (1) BR9406946A (https=)
CA (1) CA2166721C (https=)
CZ (1) CZ3696A3 (https=)
EG (1) EG20513A (https=)
FI (1) FI943208L (https=)
HU (1) HUT74170A (https=)
IL (1) IL110175A (https=)
MX (1) MX9405132A (https=)
NO (1) NO305029B1 (https=)
NZ (1) NZ266525A (https=)
PL (1) PL312426A1 (https=)
RU (1) RU2131876C1 (https=)
TW (1) TW316904B (https=)
WO (1) WO1995001980A1 (https=)
ZA (1) ZA944844B (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL319758A1 (en) * 1994-10-20 1997-08-18 Pfizer Bicyclic tetrahydropyrasole pyridines and their application as medicines
JP3107827B2 (ja) * 1995-06-06 2000-11-13 ファイザー・インコーポレーテッド トリサイクリック５，６−ジヒドロ−９Ｈ−ピラゾロ［３，４−ｃ］−１，２，４−トリアゾロ［４，３−ａ］ピリジン類
AP932A (en) * 1996-08-26 2001-02-02 Pfizer Tricyclic 5,6-dihydro-9H-pyrazolo (3,4c)-1,2,4,-triazolo (4,3-a) pyridines.
US6262040B1 (en) * 1996-09-04 2001-07-17 Pfizer Inc Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF)
NZ503432A (en) * 1997-09-26 2002-11-26 Zentaris Gmbh Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
DE69921358T2 (de) 1998-12-23 2006-03-09 Bristol-Myers Squibb Pharma Co. Stickstoffhaltige heterobicyclen als faktor-xa-hemmer
US6858616B2 (en) 1998-12-23 2005-02-22 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor Xa inhibitors
US6326495B2 (en) 1999-04-30 2001-12-04 Pfizer Inc. Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4H-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein
EP1212089B1 (en) 1999-08-21 2006-03-22 ALTANA Pharma AG Synergistic combination of roflumilast and salmeterol
TWI243055B (en) * 2000-04-13 2005-11-11 Nippon Zoki Pharmaceutical Co Pharmaceutical composition for use in treatment of dermatitis
ES2349762T3 (es) * 2000-08-10 2011-01-11 Pfizer Italia S.R.L. Biciclo-pirazoles activos como inhibidores de quinasas, procedimientos para su preparación y composiciones farmacéuticas que los comprenden.
EP1309593B1 (en) * 2000-08-14 2006-03-15 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
US6960595B2 (en) * 2001-03-23 2005-11-01 Bristol-Myers Squibb Pharma Company 5-6 to 5-7 Heterobicycles as factor Xa inhibitors
CA2444571A1 (en) 2001-04-18 2002-10-31 Bristol-Myers Squibb Company 1, 4, 5, 6-tetrahydropyrazolo-¬3, 4-c|-pyridin-7-ones as factor xa inhi bitors
CA2441772A1 (en) 2001-04-18 2002-10-31 Bristol-Myers Squibb Company 1,4,5,6-tetrahydropyrazolo-¬3,4-c|-pyridin-7-ones as factor xa inhibitors
US7902179B2 (en) 2001-04-26 2011-03-08 Ajinomoto Co., Inc. Heterocyclic compounds
CA2461202C (en) * 2001-09-21 2011-07-12 Donald Pinto Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
KR101312736B1 (ko) 2003-02-27 2013-09-27 팔라우 파르마 에스에이 피라졸로피리딘 유도체
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
MXPA05010373A (es) 2003-04-01 2005-12-05 Applied Research Systems Inhibidores de fosfodiesterasas en infertilidad.
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
TW200618800A (en) * 2004-08-03 2006-06-16 Uriach Y Compania S A J Heterocyclic compounds
DE102005031580A1 (de) * 2005-07-06 2007-01-11 Aicuris Gmbh & Co. Kg Substituierte Sulfolanylpyrazole und ihre Verwendung
PE20081889A1 (es) * 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
ES2664873T3 (es) 2011-03-01 2018-04-23 Synergy Pharmaceuticals Inc. Proceso de preparación de agonistas de guanilato ciclasa C
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
KR102456567B1 (ko) 2013-08-09 2022-10-19 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
CN110357888A (zh) * 2018-04-09 2019-10-22 南京药捷安康生物科技有限公司 杂环磷酸二酯酶抑制剂及其用途
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340269A (en) * 1964-09-08 1967-09-05 Ciba Geigy Corp 1-substituted 4-acyl-2, 3-dioxo-piperidine
US3365459A (en) * 1964-09-08 1968-01-23 Ciba Geigy Corp Certain tetrahydro pyrazolo-pyridine and pyrazolo-piperidine derivatives
EP0531901A2 (en) * 1991-09-09 1993-03-17 Fujisawa Pharmaceutical Co., Ltd. Condensed pyrazole derivatives with interleukin-1 and tumour necrosis factor inhibitory activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1463883A (fr) * 1964-09-08 1966-07-22 Ciba Geigy Procédé de préparation de triaza-composés bicycliques
HU183325B (en) * 1981-02-11 1984-04-28 Richter Gedeon Vegyeszet Process for preparing new apovincaminol-3',4',5'-trimethoxy-benzoates substituted with a nitro group
DE3269604D1 (en) * 1981-06-26 1986-04-10 Schering Corp Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
FR2525602A1 (fr) * 1982-04-21 1983-10-28 Synthelabo Imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
US4668686A (en) * 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340269A (en) * 1964-09-08 1967-09-05 Ciba Geigy Corp 1-substituted 4-acyl-2, 3-dioxo-piperidine
US3365459A (en) * 1964-09-08 1968-01-23 Ciba Geigy Corp Certain tetrahydro pyrazolo-pyridine and pyrazolo-piperidine derivatives
EP0531901A2 (en) * 1991-09-09 1993-03-17 Fujisawa Pharmaceutical Co., Ltd. Condensed pyrazole derivatives with interleukin-1 and tumour necrosis factor inhibitory activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CA，VOI.86(5),29733C 1997.1.1 Kametani,Tetsujietal *

Also Published As

Publication number Publication date
HU9503934D0 (en) 1996-03-28
BR9406946A (pt) 1996-08-06
TW316904B (https=) 1997-10-01
ZA944844B (en) 1996-01-05
RU2131876C1 (ru) 1999-06-20
FI943208A0 (fi) 1994-07-05
PL312426A1 (en) 1996-04-29
WO1995001980A1 (en) 1995-01-19
CA2166721C (en) 1999-07-27
FI943208A7 (fi) 1995-01-07
AU695301B2 (en) 1998-08-13
JP2944048B2 (ja) 1999-08-30
MX9405132A (es) 1995-01-31
NO960056L (no) 1996-01-05
KR100228949B1 (ko) 1999-11-01
NO960056D0 (no) 1996-01-05
JPH08507084A (ja) 1996-07-30
IL110175A0 (en) 1994-10-07
AU6805794A (en) 1995-02-06
KR960703852A (ko) 1996-08-31
FI943208L (fi) 1995-01-07
NO305029B1 (no) 1999-03-22
IL110175A (en) 2000-01-31
HUT74170A (en) 1996-11-28
EP0707585A1 (en) 1996-04-24
CA2166721A1 (en) 1995-01-19
CZ3696A3 (en) 1997-06-11
NZ266525A (en) 1997-10-24
EG20513A (en) 1999-06-30
CN1129940A (zh) 1996-08-28

Similar Documents

Publication Publication Date Title
CN1048015C (zh) 双环四氢吡唑并吡啶类化合物
CN1046274C (zh) 用作消炎剂的异噁唑啉化合物
JP3554337B2 (ja) インダゾール誘導体、およびホスホジエステラーゼ（ｐｄｅ）タイプ４と腫瘍壊死因子（ｔｎｆ）産生の阻害剤としてのインダゾール誘導体の使用
CN1050129C (zh) 二环四氢吡唑并吡啶和其作为药物的应用
CN102317287B (zh) 作为磷酸二酯酶抑制剂、用于治疗皮肤病的三唑并吡啶化合物
EP0672031A1 (en) Catechol diethers as selective pde iv? inhibitors
NO341965B1 (no) Benzimidazolmodulatorer av VR1
JP2016539989A (ja) Ｒｏｒガンマモジュレータとして有用な二環式ヘテロアリールインドール同族体
JP7836534B2 (ja) Ｄ－アミノ酸オキシダーゼ（ｄａａｏ）阻害剤としての新規な置換ベンゾイミダゾール誘導体
EA008801B1 (ru) Получение арилалкилкарбаматных производных и их применение в терапии
WO2019191424A1 (en) Glun2c/d subunit selective antagonists of the n-methyl-d-aspartate receptor
WO2002072567A2 (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
WO1997011054A1 (fr) Composes d'acide benzoique et leur emploi medical
HK40098861A (zh) 作为d-胺基酸氧化酶(daao)抑制剂之新颖经取代苯并咪唑衍生物
HK1000699A (en) Bicyclic tetrahydro pyrazolopyridines and their use as medicaments
CN101119724A (zh) 作为趋化因子受体调节剂的取代吡唑
KR20160095139A (ko) Ror 감마 조절인자로서 유용한 2환식 헤테로아릴 인돌 유사체
TW201326148A (zh) 做為ｔｒｐｖ３拮抗劑的色烯酮衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee